Concert Pharmaceuticals (NASDAQ: CNCE) and Blueprint Medicines (NASDAQ:BPMC) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.
This table compares Concert Pharmaceuticals and Blueprint Medicines’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility & Risk
Concert Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Concert Pharmaceuticals and Blueprint Medicines, as reported by MarketBeat.
||Strong Buy Ratings
Concert Pharmaceuticals currently has a consensus target price of $24.00, indicating a potential upside of 18.46%. Blueprint Medicines has a consensus target price of $83.78, indicating a potential upside of 7.43%. Given Concert Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Concert Pharmaceuticals is more favorable than Blueprint Medicines.
Earnings & Valuation
This table compares Concert Pharmaceuticals and Blueprint Medicines’ gross revenue, earnings per share and valuation.
||Earnings Per Share
Concert Pharmaceuticals has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Concert Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
67.4% of Concert Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.8% of Blueprint Medicines shares are owned by institutional investors. 10.1% of Concert Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Concert Pharmaceuticals beats Blueprint Medicines on 7 of the 13 factors compared between the two stocks.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company’s product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
About Blueprint Medicines
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.